Matthew Nicholson

Dr. Matthew Nicholson

Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MNMatthew Nicholson
Matthew Nicholson
NCNoel Chan
Noel Chan
VBVinai Bhagirath
Vinai Bhagirath
JGJeffrey Ginsberg
Jeffrey Ginsberg
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.

14 July 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
MNMatthew Nicholson
Matthew Nicholson
LNLeonie Naeije
Leonie Naeije
AHAnna R. Hayden
Anna R. Hayden
AMAndre Mattman
Andre Mattman
DDDavid Dix
David Dix
LCLuke Y.C. Chen
Luke Y.C. Chen
Etoposide‐based treatment is the standard of care for adult HLH in many centers, yet there remains a paucity of data regarding treatment outcomes. We conducted a retrospective study of 23 adults treated with etoposide‐based therapy compared to 10 pediatric HLH cases at a single center. At diagnosis, the median serum ferritin was 20,071 µg/L and 937 µg/L in adults and children, respectively; median sIL‐2r was 14,524 U/mL and 4,478 U/mL. Biochemical response to treatment was high, with 21/23 adults achieving >75% reduction in serum ferritin, but one year survival was only 7/21 compared to 7/10 in pediatric cases.